ICCON
TYRA icon

Investment Counsel Company of Nevada’s Tyra Biosciences TYRA Stock Holding History

Investment Counsel Company of Nevada’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85,020
Closed -$2.24M – 110
2025
Q4 		$2.24M Hold
85,020
– – 4.8% 4
2025
Q3 		$1.19M Hold
85,020
– – 2.42% 10
2025
Q2 		$814K Hold
85,020
– – 1.67% 13
2025
Q1 		$791K Hold
85,020
– – 1.8% 11
2024
Q4 		$1.18M Buy
+85,020
New +$1.54M 3% 8

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Investment Counsel Company of Nevada's TYRA Position: Q1 2026 in Review

Investment Counsel Company of Nevada sold out of Tyra Biosciences (TYRA) in Q1 2026, closing a stake of 85,020 shares — an estimated $2.24M sold.

Investment Counsel Company of Nevada first reported a position in TYRA in Q4 2024 and held it in 5 quarters. The position peaked at $2.24M in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Investment Counsel Company of Nevada reported no remaining Tyra Biosciences position as of Q1 2026 after selling out during the quarter.
  • Investment Counsel Company of Nevada sold 85,020 Tyra Biosciences shares in Q1 2026, an estimated $2.24M.
  • Investment Counsel Company of Nevada first reported a position in Tyra Biosciences in Q4 2024 and held it in 5 quarters.
  • Investment Counsel Company of Nevada's Tyra Biosciences position peaked at $2.24M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Investment Counsel Company of Nevada's 13F filing for Q1 2026, filed 15 May 2026.